Hongdan Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hongdan Lu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Hongliang Xin
Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China
1 shared publication Lingyan Lv
Department of Pharmacy, The Jiangyin Clinical College of Xuzhou Medical University, Jiangyin, China
1 shared publicationShengnan Li
Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing, China
1 shared publicationWei Lv
Department of Pharmacy, The Jiangyin Clinical College of Xuzhou Medical University, Jiangyin, China
1 shared publicationYijiao Liu
Department of Pharmacy, The Jiangyin Clinical College of Xuzhou Medical University, Jiangyin, China
1 shared publication
Latest Publications
- Open Access
- 31 May 2022
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 20 (1) , 1-31
Advances of nano drug delivery system for the theranostics of ischemic stroke
From the global perspective, stroke refers to a highly common cause of disability and death. Ischemic stroke (IS), attributed to blood vessel blockage, preventing the flow of blood to brain, acts as the most common form of stroke. Thus far, thrombolytic therapy is the only clinical treatment for IS with the approval from the FDA. Moreover, the physiology barrier complicates therapeutically and diagnostically related intervention development of IS. Accordingly, developing efficient and powerful curative approaches for IS diagnosis and treatment is urgently required. The advent of nanotechnology has brought dawn and hope to better curative and imaging forms for the management of IS. This work reviews the recent advances and challenges correlated with the nano drug delivery system for IS therapy and diagnosis. The overview of the current knowledge of the important molecular pathological mechanisms in cerebral ischemia and how the drugs cross the blood brain barrier will also be briefly summarized.Graphical Abstract
- 31 May 2022
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 20 (1) , 1-31
Open AccessAdvances of nano drug delivery system for the theranostics of ischemic stroke
From the global perspective, stroke refers to a highly common cause of disability and death. Ischemic stroke (IS), attributed to blood vessel blockage, preventing the flow of blood to brain, acts as the most common form of stroke. Thus far, thrombolytic therapy is the only clinical treatment for IS with the approval from the FDA. Moreover, the physiology barrier complicates therapeutically and diagnostically related intervention development of IS. Accordingly, developing efficient and powerful curative approaches for IS diagnosis and treatment is urgently required. The advent of nanotechnology has brought dawn and hope to better curative and imaging forms for the management of IS. This work reviews the recent advances and challenges correlated with the nano drug delivery system for IS therapy and diagnosis. The overview of the current knowledge of the important molecular pathological mechanisms in cerebral ischemia and how the drugs cross the blood brain barrier will also be briefly summarized.Graphical Abstract